Business Wire - October 16, 2002

This joint venture will mark a formidable entry platform for Ranbaxy into the South African anti-retroviral market. Adcock Ingram will leverage its strong distribution network and leadership position in the pharmaceutical private market and hospital sector to market Ranbaxy's range of anti-retroviral products.

Ranbaxy has been on the forefront in addressing the healthcare needs by providing cost-effective and quality medicines. In July 2002 the Company's select range of anti-AIDS drugs received approval from the World Health Organisation (WHO), bringing the products within the purview of WHO approved list of anti-AIDS drugs. Ranbaxy markets its anti-AIDS range of products in several countries including Africa. Applications for registration for most of these products have been lodged with the South African Medicines Control Council.

Commenting on the development, Dr Brian W. Tempest, President, Pharmaceuticals, Ranbaxy Laboratories Limited said, "This is a major step forward in deepening our business in South Africa and we are confident that the JV will realise a win-win situation for both the companies."

Chief Executive of Adcock Ingram, Mike Norris said, "HIV infections have reached unprecedented proportions. It is estimated that 40 million adults and more than 10 million orphans are living with HIV/AIDS worldwide. South Africa ranks amongst the worst affected countries in the world with an estimated 5 million people being infected with the virus. Research has shown that HIV/AIDS can be managed cost-effectively like any other chronic disease and the health outcomes of HIV-positive patients can be improved with anti-retroviral therapy. The key to successful health outcomes is the availability of a comprehensive range of therapies. Even though this would be low margin business, the expected volumes would contribute to business growth.

"We've some way to go before the joint venture gets off the ground but the foundation has been established. Next steps include the appointment of appropriately qualified and experienced people to manage the joint venture company and the completion of a business plan," he concluded.

Adcock Ingram is South Africa's leading pharmaceutical company involved in the marketing, distribution and supply of branded and generic prescription medicines and self-medication products. Adcock Ingram Critical Care is the market leader in the hospital market supplying a range of life-saving and life-sustaining intravenous solutions, infusion pumps and systems, medical diagnostics, blood and renal dialysis products. The company also supplies a range of personal care and home care products. Adcock Ingram is a wholly owned subsidiary of Tiger Brands -- a leading food and healthcare company.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets branded generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 25 countries and manufacturing operations in 7 countries.

CONTACT: Ranbaxy Laboratories Ltd.

B.K.Raizada, Tel (Direct): 6002072/6002075

bimal.raizada@ranbaxy.com

SOURCE: Ranbaxy Laboratories Ltd.

021016
BW021012

Copyright © 2002 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .